ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63

Rare prostate carcinomas aberrantly express p63 and have an immunophenotype intermediate between basal and luminal cells. Here, we performed gene expression profiling on p63‐expressing prostatic carcinomas and compared them to usual‐type adenocarcinoma. We identify ETS2 as highly expressed in p63‐expressing prostatic carcinomas and benign prostate basal cells, with lower expression in luminal cells and primary usual‐type adenocarcinomas.

[1]  A. D. De Marzo,et al.  MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer , 2018, The Journal of pathology.

[2]  Toby C. Cornish,et al.  Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides , 2017, American journal of clinical pathology.

[3]  S. Tomlins,et al.  Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. , 2017, The Journal of molecular diagnostics : JMD.

[4]  W. Isaacs,et al.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer , 2017, Clinical Cancer Research.

[5]  B. Trock,et al.  SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. , 2016, The Journal of urology.

[6]  R. Bronson,et al.  Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression. , 2016, Cancer research.

[7]  Luis A. Martinez.  Mutant p53 and ETS2, a Tale of Reciprocity , 2016, Front. Oncol..

[8]  B. Trock,et al.  Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.

[9]  S. Signoretti,et al.  ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. , 2015, Human pathology.

[10]  A. Sangoi,et al.  Prostate Adenocarcinomas Aberrantly Expressing p63 Are Molecularly Distinct from Usual-Type Prostatic Adenocarcinomas , 2014, Modern Pathology.

[11]  P. Chambon,et al.  Luminal cells are favored as the cell of origin for prostate cancer. , 2014, Cell reports.

[12]  Anirban P. Mitra,et al.  A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy , 2013, Prostate Cancer and Prostatic Disease.

[13]  J. Epstein,et al.  Aberrant Expression of p63 in Adenocarcinoma of the Prostate: A Radical Prostatectomy Study , 2013, The American journal of surgical pathology.

[14]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[15]  B. Czerniak,et al.  The p63 Protein Isoform ΔNp63α Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells , 2012, The Journal of Biological Chemistry.

[16]  I. Kubacka,et al.  Mutant p53 cooperates with ETS2 to promote etoposide resistance. , 2012, Genes & development.

[17]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[18]  T. Golub,et al.  mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[20]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[21]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[22]  R. Dhir.  Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases , 2009 .

[23]  J. Epstein,et al.  Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases , 2008, The American journal of surgical pathology.

[24]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[25]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[26]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[27]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[28]  C. Hauser,et al.  Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness , 2000, Oncogene.